Search Results
Mar 25, 2026, 06:22 ET WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
all stakeholders on a single, synchronized source of truth, the portal strengthens strategic partnerships and accelerates the journey from DNA to IND to BLA without the delays of conventional reporting cycles.As a global leading digital CRDMO, WuXi Biologics is embedding digital capability
More news about: WuXi Biologics
Mar 24, 2026, 22:40 ET Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
clinical needs. These include IO 2.0 combinations with other immune checkpoint inhibitors (ICIs), mRNA-based personalized cancer vaccines (such as AK154), DNA-based therapeutics, and additional novel therapeutic platforms. This milestone underscores Akeso's disciplined execution in translating proprietary
More news about: Akeso, Inc.
Mar 24, 2026, 20:01 ET TUBORG TELLS GEN Z 'YOU DON'T HAVE TO' AS PART OF THEIR NEW CAMPAIGN
March 25, 2026 /PRNewswire/ -- The new creative campaign stands behind those challenging societal norms, reflecting the spirit and DNA of the brand
More news about: Tuborg
Mar 24, 2026, 20:01 ET अपने नए अभियान के तहत TUBORG ने GEN Z से 'YOU DON'T HAVE TO' कहा
कोपेनहेगन, डेनमार्क, 25 मार्च, 2026 /PRNewswire/ -- ब्रांड की भावना और DNA को प्रतिबिंबित करते हुए नया रचनात्मक अभियान चुनौतीपूर्ण सामाजिक मानदंडों का समर्थन करता है।
More news about: Tuborg
Mar 24, 2026, 13:50 ET MDA SPACE PROVIDES MARKET UPDATE
vision into an achievable mission – bringing to bear a one-of-a-kind mix of experience, engineering excellence and wide-eyed wonder that's been in our DNA since day one. For those who dream big and push boundaries on the ground and in the stars to change the world for the better, we'll take you there. For
More news about: MDA Space
Mar 24, 2026, 10:00 ET Advanced Cell-based Therapy Booming the Success for Healthcare Sector
cellular science to clinical reality. Prime Medicine (NASDAQ: PRME) is developing prime editing — a next-generation gene editing platform that rewrites DNA without cutting both strands, reducing off-target risks that have haunted earlier CRISPR approaches. The precision is remarkable, but the path from edited
More news about: USA News Group
Mar 24, 2026, 09:32 ET Leva Brasil Logística: Da origem em Monte Mor à conexão com mais de 20 estados brasileiros
indiretos, fortalecendo a economia e o ecossistema de transporte do interior paulista", destaca.Especialização e Tecnologia: O DNA da EficiênciaAo longo dos anos, a Leva Brasil, empresa do grupo CBP Brasil, consolidou-se em um nicho que exige precisão extrema: o transporte
More news about: CBP Brasil
Mar 24, 2026, 08:00 ET SpectraCell Laboratories: Baseline Nexus: Personalized Longevity & Early Disease Detection Test
functional health. Methodology.The analytical technique implemented, utilizes metabolically active peripheral lymphocytes to measure DNA synthesis. This method is contingent upon a specific, meticulously crafted culture medium that contains absolutely no serum or protein. The exclusion
More news about: SpectraCell Laboratories
Mar 24, 2026, 08:00 ET John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening
screening options for adults aged 45 or older who are at average risk for the disease. The Cologuard test revolutionized CRC screening by detecting specific DNA markers and blood in stool associated with cancer and precancer, allowing patients to complete the collection kit at home without special preparation
More news about: Abbott
Mar 24, 2026, 07:57 ET RYBODYN ANNOUNCES SEED FINANCING TO ADVANCE AI-DRIVEN DISCOVERY OF HIDDEN CANCER TARGETS
largely run out of it.RyboDyn is looking somewhere else entirely.For decades, much of the human genome, nearly 98%, was considered "junk" DNA. We now know that some of these regions are transcriptionally active, yet they remain largely invisible to conventional sequencing approaches. RyboDyn
More news about: RyboDyn
Mar 24, 2026, 07:44 ET WuXi Biologics Reports Record 2025 Annual Results
During the Reporting Period, the Group introduced WuXia™ TrueSite, a targeted-integration CHO cell line platform that enables 6-month DNA-to-IND timelines, while delivering 8+ g/L mAb titers and >99% expression stability across 60 generations. The Group also expanded its high-dose drug
More news about: WuXi Biologics
Mar 24, 2026, 07:00 ET Triquetra Health Launches FolinicActive Kids -- Only USDA Organic Folinic Acid Formula with Multi-Pathway Folate Flexibility, Designed for Children Ages 1-18
supplement is now available on Amazon, offering multi-pathway folate flexibility that gives growing bodies metabolic choices — directing active folate toward DNA synthesis for healthy growth, purine biosynthesis for cellular energy, or the methylation cycle to help support their growing brain, based on what developing
More news about: Triquetra Health LLC
Mar 23, 2026, 14:38 ET Omnicom Production Accelerates North America Momentum with New Leadership Team
Alissa's leadership in North America, we have been able to be at the vanguard of this evolution while retaining our creative DNA. The addition of Deborah, JT, and Steve, three of the most progressive leaders in our industry, accelerates our
More news about: Omnicom Production
Mar 23, 2026, 13:33 ET PANTHERx® Rare Selected by UCB as the Exclusive Specialty Pharmacy for the Distribution of KYGEVVI™
Thymidine Kinase 2 Deficiency TK2d is a rare, inherited genetic disorder that affects the body's ability to produce and repair mitochondrial DNA (mtDNA). Conditions that cause low levels of mtDNA, including TK2d, can be called mitochondrial depletion syndromes. Symptoms of TK2d can include muscle
More news about: PANTHERx Rare Pharmacy
Mar 23, 2026, 10:00 ET Appspace Ends the "AI Bolt-On" Era with Native Workplace Intelligence
extending Appspace's lead in the workplace experience category it has defined.AI as native DNA, not a layered-on featureThe Custom Assistants Framework is woven into the native DNA of the Appspace platform. This level of context allows assistants to move beyond insight and into immediate
More news about: Appspace, Inc.
Mar 23, 2026, 09:09 ET Hotel Linen Manufacturer HANBI Optimizes Hotel ROI with 30% More Durable, High-Hygiene Bedding
Room Accessories: From hotel pillows to ergonomic slippers and bespoke amenity kits that align with a brand's unique DNA.Market Validation & Global ReachLate shipments are a constant headache for hotel managers. HANBI avoids this drama
More news about: Guangxi Hanbi Textile Co., Ltd
Mar 23, 2026, 09:00 ET Dataminr Redefines Cyber Defense with AI-Powered Client-Tailored Intelligence and Autonomous Threat and Exposure Management
critical business issues, from superhuman speed attacks to the complexity of fragmented technology stacks. We believe security must be built into the DNA of an organization's architecture, and our partnership with Dataminr allows us to deliver on that promise. Dataminr for Cyber Defense is the first platform
More news about: Dataminr
Mar 23, 2026, 08:55 ET OSR Holdings, VXM01 라이센스 거래 구조 개편-- 최대 8억 1,500만 달러 규모의 수익을 모회사가 직접 수령하는 구조로
유보합니다.글로벌 라이센스 본 계약의 체결 목표 시한은 이사회 승인 및 독립적인 공정성 의견서(Fairness Opinion) 수령을 조건으로 2026년 4월 30일로 그대로 유지됩니다.VXM01은 VEGFR을 표적으로 하는 경구용 DNA 기반 항암백신으로, 임상 2상 이상 후기 임상 단계에 진입할 준비가 된 자산입니다.주요 요약자회사를 거치치 않고 직접 수령: 마일스톤 및 로열티를 OSR Holdings, Inc.에 직접
More news about: OSR Holdings
Mar 23, 2026, 08:41 ET Intelligenome Announces R&D Subaward Agreement with Cornell University to Advance Rapid Point-of-Care Tuberculosis Diagnosis
human health. Under the agreement, Intelligenome will contribute its point-of-care testing (POCT) platform to a program centered on cell-free DNA (cfDNA) TB detection from respiratory and blood samples. The company's work will support advancement of a portable lab-in-tube assay designed to simplify
More news about: Intelligenome
Mar 23, 2026, 08:00 ET Stealth BioTherapeutics Announces MRC Business Engagement Fund Grant to Advance Mitochondrial Disease Research
is studying elamipretide in additional indications, including dry age-related macular degeneration and primary mitochondrial disease due to nuclear DNA mutations, including in polymerase gamma, and is developing its next-in-class clinical-stage candidate, bevemipretide, for ophthalmic and neurological
More news about: Stealth BioTherapeutics Inc.
Mar 23, 2026, 07:30 ET HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant
More news about: Soligenix
Mar 23, 2026, 07:24 ET Interna Therapeutics Announces Human Challenge Trial Agreement with the University of Oxford to Advance Intranasal MNM-siRNA SARS-CoV-2 Prophylaxis Program
platform based on its proprietary Molecular Nano Motor (MNM technology. The platform enables efficient delivery of macromolecule drugs – including siRNA, DNA, and peptides – into cells and tissues that have historically been difficult to access. Interna is advancing programs in respiratory viral infections,
More news about: Interna Therapeutics
Mar 23, 2026, 07:00 ET BioLineRx Reports 2025 Financial Results and Provides Corporate Update
month -- GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms -- Management to host conference call today, March 23, at 8:30 am EDT -TEL
More news about: BioLineRx Ltd.
Mar 20, 2026, 14:18 ET Persistent ernennt Hari S. Abhyankar zum Executive Vice President und Global Head of Private Equity and Professional Services
grundlegend anderen Ansatz, der Strategie und Umsetzung miteinander verbindet und die Ergebnisse auf das gesamte Portfolio skaliert. Die technikorientierte DNA von Persistent und der Fokus auf KI-gesteuerte Transformation versetzen das Unternehmen in eine starke Position, um diesem Bedarf gerecht zu werden.
More news about: Persistent Systems
Mar 20, 2026, 09:06 ET MDA SPACE ANNOUNCES EXERCISE OF OVER-ALLOTMENT OPTION IN INITIAL PUBLIC OFFERING IN THE UNITED STATES
vision into an achievable mission – bringing to bear a one-of-a-kind mix of experience, engineering excellence and wide-eyed wonder that's been in our DNA since day one. For those who dream big and push boundaries on the ground and in the stars to change the world for the better, we'll take you there.Forward-Looking
More news about: MDA Space